Sagimet BiosciencesSTU:0O2 +1.66%10 Equity-to-Asset is 0.95 as of Mar. 2026, which is 1% above its 10-year median of 0.94. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,420 Biotechnology companies, Sagimet Biosciences ranks better than 93.94% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Sagimet Biosciences Equity-to-Asset Related Terms
Sagimet Biosciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0O2 vs NGNE, UPB, STTK: Equity-to-Asset Comparison
For the Biotechnology subindustry, Sagimet Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Sagimet Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences (STU:0O2) has a Equity-to-Asset of 0.95 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sagimet Biosciences and its competitors. This is near median its historical median of 0.94. According to the industry distribution chart, Sagimet Biosciences ranks #86 out of 1420 companies in the Biotechnology industry, placing it in the top 6.1%.
Is Sagimet Biosciences' Equity-to-Asset too high?
Sagimet Biosciences' current Equity-to-Asset of 0.95 is near median its 10-year median of 0.94. The Biotechnology industry median Equity-to-Asset is 0.68. Sagimet Biosciences' value of 0.95 is 39.7% above this industry median. Based on the distribution chart, Sagimet Biosciences ranks #86 out of 1420 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Equity-to-Asset compare to NGNE and UPB?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #86 out of 1420 companies for Equity-to-Asset. This places Sagimet Biosciences in the top 6% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Sagimet Biosciences' value of 0.95 is 39.7% above this benchmark. While the company's 10-year median is 0.94 vs. the industry median of 0.68, Sagimet Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sagimet Biosciences's current Equity-to-Asset of 0.95 is 39.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sagimet Biosciences and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sagimet Biosciences's current Equity-to-Asset is 0.95, which is near median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Equity-to-Asset of 0.95. The current Equity-to-Asset is 0.95, which is near median its 10-year median of 0.94 and 39.7% above the Biotechnology industry median of 0.68. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Equity-to-Asset is 0.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score
Get the complete analysis for STU:0O2
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
